I'm LongbridgeAI, I can summarize articles.Amgen gained 1.11% this week to close at $437.23, about 1.02 percentage points ahead of the S&P 500. The week was choppy but tilted upward: the stock dipped to $426 on Monday, pushed higher through Tuesday and Wednesday, hit a week high of $445.815 on Thursday, then pulled back on Friday to settle at $437.23. The weekly range was 4.62%, and average daily volume ran about 12% below the 60-day median, leaving a pattern of a rally with a small late-week giveback.
The Week
Amgen gained 1.11% this week to close at $437.23, about 1.02 percentage points ahead of the S&P 500. The week was choppy but tilted upward: the stock dipped to $426 on Monday, pushed higher through Tuesday and Wednesday, hit a week high of $445.815 on Thursday, then pulled back on Friday to settle at $437.23. The weekly range was 4.62%, and average daily volume ran about 12% below the 60-day median, leaving a pattern of a rally with a small late-week giveback.
Key Events
The main company-specific story came early in the week, as Amgen said Repatha cut the risk of death by 20% in patients at high risk for a first heart attack or stroke. Midweek, UK regulators suspended Tavneos for new patients, citing unreliable data and raising the prospect of withdrawal, which offset part of the positive momentum. The company also announced it would present at the Wells Fargo Healthcare Conference webcast. Other headlines were mostly routine holdings changes and insider filings, with no new material announcements during the week.
Analyst Ratings
Across 34 firms covering Amgen, 10 rate it buy, 4 rate it overweight, 16 rate it hold, 2 rate it underweight and 2 rate it sell, leaving 14 at buy or overweight and 4 at underweight or sell. The consensus recommendation is buy, but the consensus target of $389.69 sits about 10.87% below the spot price of $437.23, meaning the shares already trade above the average broker target. Targets range from $230 to $457, a wide spread. Within the biotech industry, Amgen ranks second out of 507 names by rating.
The Week Ahead
On the macro side, the NFIB small business confidence index lands on 8 September, followed on 10 September by US initial jobless claims, final demand PPI and the 10-year Treasury auction results. Rate and inflation readings remain relevant for biotech valuations. On the company front, the UK regulatory path for Tavneos is still developing, and the Wells Fargo Healthcare Conference webcast should give management a chance to offer more colour on the pipeline.
In Short
The signals this week are mixed: Repatha supplied a positive mortality data point, while Tavneos faced a UK suspension. The consensus rating is still buy, yet the consensus target is below spot, and the latest session showed zero large-lot outflow with net buying skewing toward small orders. What comes next is whether the Tavneos regulatory process stabilises, and whether the 10 September PPI and claims data shift rate expectations across the biotech group.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.